Polypeptide Hormones Eptifibatide CAS 148031-34-9 for Acute Coronary Syndrome

November 01, 2018

Model NO.: CAS No.: 148031-34-9
CAS No.: 148031-34-9
Molecular Weight: 831.96
Appearance: White Powder
Molecular Formula: C35h49n11o9s2
Payment: T/T, Western Union and Money Gram
Delivery: Within 24hours After Your Payment
Express: EMS, DHL, FedEx, etc(Door-to-Door)
Trademark: YIJING
Transport Package: According to Every Customers′s Requirements
Specification: GMP SGS
Origin: Sh
HS Code: 5402453000
Model NO.: CAS No.: 148031-34-9
CAS No.: 148031-34-9
Molecular Weight: 831.96
Appearance: White Powder
Molecular Formula: C35h49n11o9s2
Payment: T/T, Western Union and Money Gram
Delivery: Within 24hours After Your Payment
Express: EMS, DHL, FedEx, etc(Door-to-Door)
Trademark: YIJING
Transport Package: According to Every Customers′s Requirements
Specification: GMP SGS
Origin: Sh
HS Code: 5402453000
Basic info:
 
Eptifibatide 
CAS No.: 148031-34-9
Molecular Formula: C35H49N11O9S2
Molecular Weight: 831.96
Appearance: White powder
Specific Rotation[20/D]: -75.0~-95.0°(C=1,1%HAc)
Amino Acids composition: ± 10%
Peptide Purity (By HPLC): >99.3% by area integration
Related Substance (By HPLC): Total Impurities (%)<2.0%;Largest Single Impurity (%)< 1.0%
Water Content (Karl Fischer): <8.0%
Peptide Content(N determination): >80%
Acetate Content: <15%
Grade : Pharmaceutical Grade
Storage: Closed, below 2 ~ 8ºC preservation
Delivery time : within 18 hours upon receipt of payment
Delivery: EMS, DHL, TNT, FedEx, UPS
Usage : Platelet glycoprotein receptor antagonist model, the third generation of antiplatelet drugs. For acute coronary syndrome (including unstable angina or non Q wave myocardial infarction) or percutaneous coronary interventional therapy (including angioplasty or atheromatous plaque excision).
 

Product introduction:
 
Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.[1] Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the so-called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
 
 Indications:
 
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI). The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide. The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.
 
 
Contraindications and precautions:
 
1. Thrombocytopenia : The drug is contraindicated in patients with platelet counts of less than 100,000 per μl because no clinical experience exists regarding such patients.
 
2. Renal insufficiency : Eptifibatide undergoes renal elimination. In such patients with renal insufficiency where a glycoprotein IIb/IIIa inhibitor is likely to provide benefit, Abciximab (trade name: Reopro) is an alternative medication.
 
3. Current bleeding tendencies or abnormally prolonged coagulation parameters observed within 30 days before starting therapy with eptifibatide is intended.
 
4. Coagulation parameters such as ACT, aPTT, TT, and PT should be followed closely during therapy and afterwards. Allergy to eptifibatide and/or other ingredients. Severe, uncontrolled hypertension.
 
5. Pregnancy : No experience exists. Pregnant patients should be treated only when clearly needed.
 
6. Lactation : No human data exists. Breast-feeding should be avoided during treatment in order to prevent damage to the newborn.
 
7. Geriatric patients : No differences in side effects compared with younger patients have been seen. Nevertheless, geriatric patients should be very closely observed for bleeding and other side-effects.
 
8. Pediatric patients : Eptifibatide is not indicated in patients below 18 years of age, because no experience exists


Our commitment:
 
1. Quality assurance
With our years of experience, advanced technology and continuous research, our quality is to fully meet the needs of the market to meet the requirements of customers, many customers use our products, we believe that the product is very good. Whether it is a powder, or liquid, yes, we all know, our liquid better.
 
2. Safe transportation
Our mode of transport is taken according to each country's situation is different transportation, while our packaging, according to the latest customs situation, constantly updated, improved our packaging, we guarantee that you receive it within 3-5 to your product.
 
3. The product diversity
Our products are powders and liquids, yes, brothers, the effect of the liquid is very good, but many people do not use liquid, so you are very lucky, you buy our powder, we can tell you the method of making the liquid If you buy a liquid, we will tell you how to filter. We absolutely guarantee that you can very safely use our products
 
4. High quality service : Our goods packing will not contain any hormone information and can be sent out from different areas of china. At present,the goods customs clearance rate we send to United states and Europe is 99%,  As for Canada, Brazil of quite high buckle close rate area, we also have a new way to get through the customs. We also have completely re-send policy to some areas.
 
 
Hot product :
 
Peptides Specification
MGF 2mg
PEG MGF 2mg
CJC-1295 with DAC 2mg
CJC-1295 without DAC 2mg
PT-141 10mg
MT-1 10mg
MT-2 10mg
GHRP-2 5mg
GHRP-2 10mg
GHRP-6  5mg
GHRP-6  10mg
Ipamorelin 2mg
Hexarelin 2mg
Sermorelin 2mg
Oxytocin 2mg
TB500 2mg
Pentadecapeptide BPC 157 2mg
Triptorelin 2mg
Tesamorelin 2mg
Gonadorelin 2mg
Gonadorelin 10mg
DSIP 2mg
Selank 5mg
 
Sarms:  
MK-2866(Ostarine)/GTx-024 CAS:1202044-20-9,841205-47-8
MK677(Ibutamoren) CAS: 159752-10-0
YK11 CAS: 431579-34-9
GW501516(Cardarine) CAS: 317318-70-0
S4(Andarine, S-40503,GTx-007) CAS: 401900-40-1
LGD4033(AICAR)/Ligandrol/Anabolicum CAS: 1165910-22-4
RAD-140/Testolone CAS: 1182367-47-0
SR9009/Stenabolic CAS: 1379686-30-2
AOD-9640 2mg
Basic info:
 
Eptifibatide 
CAS No.: 148031-34-9
Molecular Formula: C35H49N11O9S2
Molecular Weight: 831.96
Appearance: White powder
Specific Rotation[20/D]: -75.0~-95.0°(C=1,1%HAc)
Amino Acids composition: ± 10%
Peptide Purity (By HPLC): >99.3% by area integration
Related Substance (By HPLC): Total Impurities (%)<2.0%;Largest Single Impurity (%)< 1.0%
Water Content (Karl Fischer): <8.0%
Peptide Content(N determination): >80%
Acetate Content: <15%
Grade : Pharmaceutical Grade
Storage: Closed, below 2 ~ 8ºC preservation
Delivery time : within 18 hours upon receipt of payment
Delivery: EMS, DHL, TNT, FedEx, UPS
Usage : Platelet glycoprotein receptor antagonist model, the third generation of antiplatelet drugs. For acute coronary syndrome (including unstable angina or non Q wave myocardial infarction) or percutaneous coronary interventional therapy (including angioplasty or atheromatous plaque excision).
 

Product introduction:
 
Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.[1] Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the so-called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
 
 Indications:
 
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI). The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide. The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.
 
 
Contraindications and precautions:
 
1. Thrombocytopenia : The drug is contraindicated in patients with platelet counts of less than 100,000 per μl because no clinical experience exists regarding such patients.
 
2. Renal insufficiency : Eptifibatide undergoes renal elimination. In such patients with renal insufficiency where a glycoprotein IIb/IIIa inhibitor is likely to provide benefit, Abciximab (trade name: Reopro) is an alternative medication.
 
3. Current bleeding tendencies or abnormally prolonged coagulation parameters observed within 30 days before starting therapy with eptifibatide is intended.
 
4. Coagulation parameters such as ACT, aPTT, TT, and PT should be followed closely during therapy and afterwards. Allergy to eptifibatide and/or other ingredients. Severe, uncontrolled hypertension.
 
5. Pregnancy : No experience exists. Pregnant patients should be treated only when clearly needed.
 
6. Lactation : No human data exists. Breast-feeding should be avoided during treatment in order to prevent damage to the newborn.
 
7. Geriatric patients : No differences in side effects compared with younger patients have been seen. Nevertheless, geriatric patients should be very closely observed for bleeding and other side-effects.
 
8. Pediatric patients : Eptifibatide is not indicated in patients below 18 years of age, because no experience exists


Our commitment:
 
1. Quality assurance
With our years of experience, advanced technology and continuous research, our quality is to fully meet the needs of the market to meet the requirements of customers, many customers use our products, we believe that the product is very good. Whether it is a powder, or liquid, yes, we all know, our liquid better.
 
2. Safe transportation
Our mode of transport is taken according to each country's situation is different transportation, while our packaging, according to the latest customs situation, constantly updated, improved our packaging, we guarantee that you receive it within 3-5 to your product.
 
3. The product diversity
Our products are powders and liquids, yes, brothers, the effect of the liquid is very good, but many people do not use liquid, so you are very lucky, you buy our powder, we can tell you the method of making the liquid If you buy a liquid, we will tell you how to filter. We absolutely guarantee that you can very safely use our products
 
4. High quality service : Our goods packing will not contain any hormone information and can be sent out from different areas of china. At present,the goods customs clearance rate we send to United states and Europe is 99%,  As for Canada, Brazil of quite high buckle close rate area, we also have a new way to get through the customs. We also have completely re-send policy to some areas.
 
 
Hot product :
 
Peptides Specification
MGF 2mg
PEG MGF 2mg
CJC-1295 with DAC 2mg
CJC-1295 without DAC 2mg
PT-141 10mg
MT-1 10mg
MT-2 10mg
GHRP-2 5mg
GHRP-2 10mg
GHRP-6  5mg
GHRP-6  10mg
Ipamorelin 2mg
Hexarelin 2mg
Sermorelin 2mg
Oxytocin 2mg
TB500 2mg
Pentadecapeptide BPC 157 2mg
Triptorelin 2mg
Tesamorelin 2mg
Gonadorelin 2mg
Gonadorelin 10mg
DSIP 2mg
Selank 5mg
 
Sarms:  
MK-2866(Ostarine)/GTx-024 CAS:1202044-20-9,841205-47-8
MK677(Ibutamoren) CAS: 159752-10-0
YK11 CAS: 431579-34-9
GW501516(Cardarine) CAS: 317318-70-0
S4(Andarine, S-40503,GTx-007) CAS: 401900-40-1
LGD4033(AICAR)/Ligandrol/Anabolicum CAS: 1165910-22-4
RAD-140/Testolone CAS: 1182367-47-0
SR9009/Stenabolic CAS: 1379686-30-2
AOD-9640 2mg


Lighting Adapter


T8-T5 Adapter System, Which replaces T8 /T10/ T12 fluorescent tubes with mechanical ballast, 40% to 45% power savings + More Environmentally friendly Components = green lighting, . Advanced technology, and  perfect performance, warm start, PF>0.99, THD<10%, wide voltage(150-270V), no flicker or hum.  And reliable quality and Long Life, ballast three years and tube 10000 hours Complies with CE use for offices, supermarkets, schools, hospitals etc.


Lighting Adapter

Lighting Adapter, T8-T5 Adapter System

Ningbo Sunfine UV lighting Co.,ltd. , http://www.uvlightings.com